Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Blue Earth Therapeutics

Request full access

Targeted radiotherapeutics for prostate cancer treatment

Oxford, United KingdomFounded 2021Biotech & Life Sciences

About Blue Earth Therapeutics

Blue Earth Therapeutics is a clinical-stage radiopharmaceutical company founded in 2021 in Oxford, UK, as a subsidiary of the Bracco Group. The company was established to advance the development of next-generation targeted radiotherapeutics for cancer treatment. David Gauden, who co-founded the sister company Blue Earth Diagnostics, led the spin-out of Blue Earth Therapeutics and serves as its CEO. His background includes over 25 years in the radiopharmaceuticals industry, with previous leadership roles at GE Healthcare and a doctorate in biochemistry from Oxford University.

The company's primary focus is on prostate cancer, with a pipeline of precision-targeted therapeutic radiopharmaceuticals. It holds exclusive worldwide rights for the therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology, which originated at the Technical University of Munich. This technology allows for the creation of theranostic compounds that can be labeled with either diagnostic or therapeutic radioisotopes for personalized medicine. The lead programs involve labeling the rhPSMA molecule with lutetium-177 (a beta emitter) and actinium-225 (an alpha emitter), aiming to deliver high radiation doses to tumors while minimizing exposure to healthy tissues.

Blue Earth Therapeutics operates on a model of advancing its proprietary drug candidates through clinical trials to gain regulatory approval. In October 2024, the company secured $76.5 million in a Series A financing round led by Soleus Capital and Sands Capital, with participation from initial investor Bracco Imaging and others. This funding supports the progression of its lead candidates, 177Lu-rhPSMA-10.1 and 225Ac-rhPSMA-10.1, into Phase 2 clinical studies. The company is actively conducting clinical trials in the US and EU and has partnered with institutions like University College London to accelerate its research.

Source: Dealroom company data

At a glance

Status
Operational
Employees
26
Open positions
None listed
Dealroom signal
47.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Precision Medicine, Biotech and Pharma, uk is8 life sciences, Radiotherapy, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Oct 2024 $77M $306M Bracco · Soleus Capital · Sands Capital Management ↗
CORPORATE SPINOUTOther financing Mar 2022 $0 — Bracco ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Blue Earth Therapeutics website traffic

Latest recorded traffic for Blue Earth Therapeutics is 30 monthly website visits, down 98.2% over the last three months. Blue Earth Therapeutics's team grew 4% over the past year.

Latest monthly visits30 3-month web change-98.2% 1-year team growth+4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Blue Earth Therapeutics in the Oxford ecosystem

Live from Dealroom

The Blue Earth Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Soleus Capital
  • Sands Capital Management

Series B and later1 investor entered at this stage

  • Bracco
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇬🇧 United Kingdom68.2%
🇺🇸 United States22.7%
🇮🇹 Italy4.5%
🇫🇷 France4.5%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Blue Earth Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Blue Earth Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.